206 related articles for article (PubMed ID: 36599630)
1. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).
Adami G; Fassio A; Rossini M; Bertelle D; Pistillo F; Benini C; Viapiana O; Gatti D
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36599630
[TBL] [Abstract][Full Text] [Related]
2. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
[TBL] [Abstract][Full Text] [Related]
3. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
4. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
5. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
6. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH; Boers M; Hartman L; Opris D; Bos R; Kok MR; Da Silva JA; Griep E; Klaasen R; Allaart CF; Baudoin P; Raterman HG; Szekanecz Z; Buttgereit F; Masaryk P; Lems W; Smulders Y; Cutolo M; Ter Wee MM
Ann Rheum Dis; 2023 Oct; 82(10):1307-1314. PubMed ID: 37541762
[TBL] [Abstract][Full Text] [Related]
7. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
Terslev L; Ostergaard M; Georgiadis S; Brahe CH; Ellegaard K; Dohn UM; Fana V; Møller T; Juul L; Huynh TK; Krabbe S; Ornbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Hetland ML
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549857
[TBL] [Abstract][Full Text] [Related]
8. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
9. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
Vodencarevic A; Tascilar K; Hartmann F; Reiser M; Hueber AJ; Haschka J; Bayat S; Meinderink T; Knitza J; Mendez L; Hagen M; Krönke G; Rech J; Manger B; Kleyer A; Zimmermann-Rittereiser M; Schett G; Simon D;
Arthritis Res Ther; 2021 Feb; 23(1):67. PubMed ID: 33640008
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
11. Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study.
Xie W; Huang H; Zhang Z
Intern Emerg Med; 2023 Sep; 18(6):1759-1767. PubMed ID: 37418144
[TBL] [Abstract][Full Text] [Related]
12. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.
Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F
Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900
[TBL] [Abstract][Full Text] [Related]
13. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
14. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
15. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
16. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
[TBL] [Abstract][Full Text] [Related]
18. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
[TBL] [Abstract][Full Text] [Related]
19. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
